Verona Pharma plc (VRNA) ADR EACH REP 8 ORD SHS SPON
$0.80
(1.94%)
- Add to watchlist
- This stock can be held in a
$0.80
(1.94%)
$0.80
(1.94%)
Business summary
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Contact details
Important dates
General stock information
- Short code:
- VRNA
- ISIN:
- US9250501064
- Market cap:
- $3.28 billion
- Shares in issue:
- 648.65 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- Great Britain
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.